Antithrombotic Drug Therapy in Cardiovascular Disease

  • Arman T. Askari
  • A. Michael Lincoff

Part of the Contemporary Cardiology book series (CONCARD)

Table of contents

  1. Front Matter
    Pages i-xi
  2. Basic Principles

    1. Front Matter
      Pages 1-1
    2. Edward F. Plow, Peter Kelly
      Pages 3-17
    3. Kandice Kottke-Marchant
      Pages 19-38
    4. John H. Cleator, Mark Robbins
      Pages 39-61
    5. Svati H. Shah, Richard C. Becker
      Pages 63-114
  3. Antithrombotic Therapy for Stable Coronary Atherosclerotic Disease

    1. Front Matter
      Pages 116-116
    2. Jinesh Kochar, J. Michael Gaziano
      Pages 117-129
    3. Marcus D. Flather, Dipak Kotecha
      Pages 131-141
  4. Antithrombotic Therapy for NSTE ACS

    1. Front Matter
      Pages 144-144
    2. Tyler L. Taigen, James E. Harvey, A. Michael Lincoff
      Pages 183-201
    3. Michael S. Kim, Robert L. Page, Ivan P. Casserly
      Pages 203-215
  5. Antithrombotic Therapy for STEMI

  6. Antithrombotic Therapy in Interventional Cardiology

    1. Front Matter
      Pages 260-260
    2. Thomas J. Helton, Samir R. Kapadia
      Pages 283-305
    3. Kristofer Dosh, Steven Steinhubl
      Pages 307-328
  7. Antithrombotic Therapy in Venous Thromboembolism

    1. Front Matter
      Pages 330-330
    2. Esther S. H. Kim, John R. Bartholomew
      Pages 331-350
    3. Stavros V. Konstantinides
      Pages 351-361
  8. Clinical Consideration

    1. Front Matter
      Pages 388-388
    2. Carmel M. Halley, Allan L. Klein
      Pages 389-403
    3. Noah Rosenthal, Brian D. Hoit
      Pages 405-423
    4. Zuheir Abrahams, George Sokos, W. H. Wilson Tang
      Pages 425-433
    5. John R. Bartholomew
      Pages 435-447
    6. Gerald C. Koenig, Hitinder S. Gurm
      Pages 449-464
  9. Back Matter
    Pages 465-475

About this book


Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Written by experts in the field, Antithrombotic Drug Therapy in Cardiovascular Disease carefully examines individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, thieneopyridines, glycoprotein IIb/IIIa inhibitors), and anticogulant therapies (unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors), non-ST-segment elevation (NSTE) ACS and ST-segment elevation myocardial infarction (STEMI). A detailed overview, Antithrombotic Drug Therapy in Cardiovascular Disease presents the evidence demonstrating the efficacy of available antithrombotic therapies in specific disease states such as atrial fibrillation, cardiomyopathy, valvular heart disease, and heparin-induced thrombocytopenia (HIT).


Antiplatelet therapies Antithrombotic therapies Atrial fibrillation Deep vein thrombosis Myocardial infarction Pulmonary embolism Thrombosis Unstable angina cardiovascular

Editors and affiliations

  • Arman T. Askari
    • 1
  • A. Michael Lincoff
    • 2
  1. 1.Western Reserve Heart CareHudsonU.S.A.
  2. 2.Dept. Cardiovascular MedicineCleveland ClinicClevelandU.S.A.

Bibliographic information

  • DOI
  • Copyright Information Humana Press 2010
  • Publisher Name Humana Press, Totowa, NJ
  • eBook Packages Medicine
  • Print ISBN 978-1-60327-234-6
  • Online ISBN 978-1-60327-235-3
  • Buy this book on publisher's site